Hans C Lee
University of Texas MD Anderson Cancer Center LAO · M.D. Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Hans C Lee as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:02 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT03031730 · Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple MyelomaNational Cancer Institute (NCI) · terminated · Plasmacytoma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma · principal investigator
- Ph1NCT02579824 · Ascending Dose and Exploratory Expansion Study of DS-3032b, an Oral MDM2 Inhibitor, in Subjects With Relapsed and/or Refractory Multiple MyelomaM.D. Anderson Cancer Center · terminated · Myeloma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:02 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Texas EXperimental Cancer Therapeutics Network - TEX CTNUM1CA186688 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FUNDA MERIC-BERNSTAM, John Sarantopoulos, James C Yao · fiscal years 2014 to 2026Named on NCT03031730
Most cited trial papers
Clinical-trial papers with this author name in multiple myeloma, ranked by citations from NIH iCite, fetched 2026-11-12 12:02 UTC. The ranking covers the 200 most relevant of 18 PubMed records, and a shared surname and initials can bring in a namesake. All 18 on PubMed
- Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.Lancet Oncol · 2020666 citationsRCR 30.2
- Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma.J Clin Oncol · 2024179 citationsRCR 22.7
- 162 citationsRCR 8.8
- 129 citationsRCR 7.1
- Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial.Lancet Haematol · 201975 citationsRCR 3.1
- Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma.Leukemia · 202162 citationsRCR 3.3
- Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study.Blood Cancer J · 202048 citationsRCR 2.0
- Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs.Bone Marrow Transplant · 201926 citationsRCR 1.1
- A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma.Blood Cancer J · 201920 citationsRCR 0.7
- Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.Lancet Haematol · 201817 citationsRCR 0.6